Clinical Updates in CSPC

ESMO 2023 Insights: "EMBARK Secondary Endpoints - Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence"

By Insights from 2023 ESMO Annual Meeting FEATURING Ugo De Giorgi

281 views

November 9, 2023

Disclaimer: This video was recorded prior to FDA approval of enzalutamide on November 17, 2023 for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

Comments 0

Login

Login

Join VuMedi

Clinical Updates in CSPC

ESMO 2023 Insights: "EMBARK Secondary Endpoints - Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence"

Treatment Intensification of High-Risk BCR Prostate Cancer

ESMO 2023 Insights: "Prognostic Role of Metastatic Site in Patients …

Year in Review: EMBARK Study and the Evolving Role of Intensified AD…

SUO 2023 Insights: "Doublets or Triplets for Patients With mCSPC - S…

EMUC 2023 Insights: "De-Escalating Strategies in mHSPC - Who, When, …

ESMO 2023 Insights: "Real-World OS With Enzalutamide & Abiraterone A…

Therapeutic Approach in mCSPC: Doublets, Triplets, and Patient Selec…

ESMO 2023 Insights: "The BonEnza Study - Changes in Bone Mineral Den…

Case-Based Clinical Updates in Prostate Cancer: 77 y/o Practicing Ph…

Treatment Landscape of mHSPC: Doublet or Triplet

Assessment and Decision Tools for Balancing Survival and Quality of …

Post-Hoc Analyses of Phase 3 ARCHES Trial: OS in Patients With mHSPC…

30 Years Perspective on Advanced Prostate Cancer: Using Biology & Pe…

Cost-Effectiveness Analysis of Seven Treatment Regimens in mHSPC: A …

A Multidisciplinary Team Approach to Prostate Cancer

Recent Prostate Cancer Updates

ESMO 2023 Insights: "Phase 3 Randomized EMBARK Study - Enzalutamide/…